Terlipressin – USA

Terlipressin – USA

IPR decision: Nov. 13, 2019

AIA Review #
Filing Date
Institution Date
Petitioner
Patent
Respondent
FINAL WRITTEN DECISION
IPR2018-00974
04/27/2018
11/14/2018
Mallinckrodt
9,655,945
BioVie, Inc.
All Challenged Claims Unpatentable
US 9,655,945 (Biovie Inc.; Exp: Jun 30, 2036) – Non-OB

1. A method for treating a patient diagnosed with ascites due to liver cirrhosis, the method comprising administering terlipressinor salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day to the patient for about one day to about 12 months.

7. A method for reducing the accumulation of ascitic fluid in the abdominal cavity in an ambulatory ascites patient, the method comprising administering to the patient terlipressin or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day for about one day to about twelve months with an ambulatory infusion pump.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved